Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Trastuzumab VC-seco-DUBA

Known as: ADC SYD985, Antibody-drug Conjugate SYD985, SYD985 
An antibody-drug conjugate (ADC) composed of the recombinant humanized anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab… Expand
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
The introduction of anti-HER2 therapies to the treatment of patients with HER2-positive breast cancer has led to dramatic… Expand
  • table 1
  • table 2
Review
2019
Review
2019
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Since the discovery of the human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers… Expand
  • figure 1
  • table 1
  • table 2
Review
2019
Review
2019
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Targeted drug delivery has improved cancer treatment significantly in recent years, although it is difficult to achieve… Expand
2018
2018
A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.
1014Background: SYD985, (vic-)trastuzumab duocarmazine, is a HER2-targeting antibody-drug conjugate with a cleavable linker… Expand
2017
2017
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
BACKGROUND Epithelial ovarian cancer (EOC) is an aggressive and heterogeneous disease. <10% of EOC demonstrate HER2/neu 3… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2017
2017
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression
Purpose: Carcinosarcomas (CS) are highly aggressive gynecologic malignancies containing both carcinomatous and sarcomatous… Expand
  • table 1
2016
2016
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody–Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression
Uterine serous carcinoma (USC) is an aggressive form of endometrial cancer. Up to 35% of USC may overexpress the HER2/neu… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2015
Highly Cited
2015
Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody-Drug Conjugate SYD985.
Antibody-drug conjugates (ADCs) that are currently on the market or in clinical trials are predominantly based on two drug… Expand
Highly Cited
2015
Highly Cited
2015
The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers
SYD985 is a HER2-targeting antibody–drug conjugate (ADC) based on trastuzumab and vc-seco-DUBA, a cleavable linker-duocarmycin… Expand
  • figure 2
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Highly Cited
2014
Highly Cited
2014
Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform
A linker-drug platform was built on the basis of a cleavable linker-duocarmycin payload for the development of new-generation… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE